Drug Target Review: Pinpointing function in cancer T cells could be new immunotherapy

UC research has found that increasing a certain function in cancer T cells could mean a new therapy

A previously unknown T cell mechanism that could explain the reason behind decreased immune function in cancer patients has been discovered. According to University of Cincinnati researchers, their finding may present a new immunotherapeutic target for patients with head and neck cancers.

The study, led by Laura Conforti and Ameet Chimote, in the Division of Nephrology and Hypertension, UC Department of Internal Medicine, revealed that a reduced interaction between a molecule called calmodulin and the ion channel KCa3.1 in the immune cells of cancer patients plays an important role in the limited function of these cells. The team performed experiments on cytotoxic T cells taken from the blood of patients with head and neck cancer.

Read the full story.

Read the news release.

Featured photo courtesy of Laura Conforti and Ameet Chimote

Related Stories

1

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.